PMC:6218602 / 6383-6932 JSONTXT

{"project":"2_test","denotations":[{"id":"30425662-21457676-41865330","span":{"begin":285,"end":287},"obj":"21457676"},{"id":"30425662-8092334-41865331","span":{"begin":545,"end":547},"obj":"8092334"}],"text":"Treatment resistance has been most characterized in schizophrenia by how responsive the positive symptom domain is to antipsychotic medications. It is estimated that 70–80% of patients with schizophrenia have a phenotype of psychosis that is responsive to dopamine-blocking treatment (13). However, in over 100 years of treatment history and despite the improvements made to the functional selectivity and potency of antipsychotic medications, 60% of patients continue to fail to achieve symptom improvement after several weeks on drug therapy (14)."}